Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin-Reference-Cited by-同舟云学术

Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin

Published:2016-10-31 Issue:1 Volume:21 Page:95-105
ISSN:1177-1062
Container-title:Molecular Diagnosis & Therapy
language:en
Short-container-title:Mol Diagn Ther

Author:

Mitchell Dominic,Guertin Jason R.,Iliza Ange Christelle,Fanton-Aita Fiorella,LeLorier Jacques

Funder

Génome Québec

Genome Canada

Pfizer Canada

Bernie O'Brien Post-Doctoral Fellowship

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40291-016-0238-8.pdf

Reference31 articles.

1. Statistics Canada, Cholesterol levels of Canadians, 2009 to 2011. 2012. http://www.statcan.gc.ca/pub/82-625-x/2012001/article/11732-eng.htm . Accessed 2013 06 08.

2. Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GB, McPherson R, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29(2):151–67. doi: 10.1016/j.cjca.2012.11.032 .

3. Adriana B. Are we overdosing on this ‘wonder drug’? The Globe and Mail. 2012. http://www.theglobeandmail.com/life/health-and-fitness/health/conditions/are-we-overdosing-on-this-wonder-drug/article4101464/ . Accessed 29 janvier 2014.

4. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40(3):567–72.

5. Chai C, James H. Working out ’til you’re sick? Doctors warn of rhabdo, a deadly condition linked to over exercising. Global news, Canada, Montreal. 2014. http://globalnews.ca/news/1082282/doctors-warn-of-rhabdo-a-deadly-condition-linked-to-over-exercising/ . Accessed 23 Jan 2016.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the Utility of Measurement Methods Applied in Economic Evaluations of Pharmacogenomics Applications;Pharmacogenomics;2024-01

2. Cost-effectiveness analysis of implementing polygenic risk score in a workplace cardiovascular disease prevention program;Frontiers in Public Health;2023-07-11

3. Pharmacogenomics of lipid-lowering agents: the impact on efficacy and safety;Personalized Medicine;2022-11-23

4. Integrating a Polygenic Risk Score for Coronary Artery Disease as a Risk‐Enhancing Factor in the Pooled Cohort Equation: A Cost‐Effectiveness Analysis Study;Journal of the American Heart Association;2022-06-21

5. A Cost–Consequence Analysis of Preemptive SLCO1B1 Testing for Statin Myopathy Risk Compared to Usual Care;Journal of Personalized Medicine;2021-10-31